Shattuck Labs Inc (STTK) News & EventsSTTKShattuck Labs Inc

Shattuck Labs to Initiate Phase 2 Trial for SL-325 in 2026

Shattuck Labs announced its plans to evaluate SL-325 in a Phase 2 clinical trial in patients with moderate to severe hidradenitis suppurativa. RECEPTIVE-HS1 Phase 2 clinical trial in patients with moderate to severe hidradenitis suppurativa expected to initiate in 2026; data from the 16-week treatment period expected in the first half of 2028. The primary endpoint is the proportion of patients achieving Hidradenitis Suppurativa Clinical Response 50 at Week 16, defined as at least a 50% reduction in AN count, with no increase in abscess or draining tunnel counts relative to baseline. Shoba Ravichandran joins Shattuck Labs as Senior Vice President, SVP, Clinical Development, and brings more than 20 years of drug development experience.

SL-325 Clinical Data Strong, Funding Expected Through 2029

As of June 30, 2026, cash and cash equivalents and short-term investments were $208.3M, as compared to $50.5 million as of June 30, 2025, expected to fund operations into 2029. "The Phase 1 clinical data for SL-325 has checked all of the boxes and positions SL-325 as a potentially winning antibody in the TL1A/DR3 axis heading into Phase 2 clinical development," said Taylor Schreiber, CEO. "The RECEPTIVE-CD1 Phase 2b clinical trial in Crohn's disease is on track to initiate in the third quarter, and is designed to establish the efficacy profile of SL-325 across three dose levels, both at induction and at maintenance time points. As we expected, clinical proof of concept for the TL1A/DR3 axis is now emerging outside of IBD. We are pleased to see this continued momentum for the class, and we believe that blocking DR3 will prove more efficacious than blocking TL1A across any indication where TL1A is implicated."

S&P and Nasdaq Bounce Back as Semiconductor Stocks Recover

The S&P and Nasdaq advanced to begin the week, bouncing back from Friday's declines as semiconductor stocks recovered some of the roughly $1T in market value erased from the chip sector late last week. The strength came despite oil prices moving higher following renewed attacks between Iran and Israel. as the commodity continues a volatile stretch. Of note, Israeli Prime Minister Benjamin Netanyahu reportedly said Israel is holding fire in Iran for now, but added that he told U.S. President Donald Trump that Israel has a full right to self-defense and that Israel will respond with "great force" if Iran attacks again.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Nvidiaand SK Hynix announced aAmazonannounced an agreement with CorningtoIngredionannounced a recommendedCampbell'sreportedand reaffirmed its FY26 guidanceAt its Worldwide Developers Conference keynote event, Apple (AAPL) unveiled new Apple Intelligence features for its apps, as well as an2. WALL STREET CALLS:Crocsto Outperform at BairdCenterspaceto Neutral at Piper SandlerVoya Financialto Strong Buy from Market Perform at Raymond JamesWall Streetof Cerebras Systemswith bullish recommendationsFervo Energysaw a bit more mixed reception infrom Wall Street firms3. AROUND THE WEB:Spotifyis hoping to become a destination for live music content, including livestreamed concerts and festivals, and has approached concert promoters regarding licensing rights to broadcast the events, Bloomberg saysThe U.K. competition regulator has launched a probe into eBay'spurchase of Depop from Etsy, Reuters reportsIn a recently published report, Hunterbrook says that Ensign Group'sbusiness model relies on "delivering inadequate care to patients while gaming data on quality, according to Hunterbrook's five-month investigation.ITA Airways will decide within the next 8 weeks on if it will sue RTX'sPratt & Whitney over engine problems that have grounded about 20% of its 80 aircraft fleet, Reuters reportsCarlylehas agreed to acquire Chung Ho Group for $700M, Bloomberg says4. MOVERS:Tango Therapeuticsgained afterfrom ongoing Phase 1/2 study of vopimetostaAmerican Batteryincreased afterwith the U.S. Department of Energy for the reinstatement of its grant awardEli Lillywas higher after itdemonstrating that women with obesity or overweight who took the highest dose of Foundayo experienced significant weight loss at every stage of menopauseShattuck Labswas lower after announcingCienafell after filing to sell5. EARNINGS/GUIDANCE:HoneywellDuluth Holdingsand backed its guidance for FY26Graham, with CEO Matthew Malone commenting on "another year of strong execution"Motorcar Partsand provided guidance for FY27VinFast Auto, with revenue up year-over-yearINDEXES:The Dow fell 80.77, or 0.16%, to 50,786.01, the Nasdaq gained 220.23, or 0.86%, to 25,929.66, and the S&P 500 advanced 21.99, or 0.30%, to 7,405.73.